The Health Sciences Authority (HSA) has issued a Dear Healthcare Professional Letter to remind clinicians that Cyklokapron (tranexamic acid) injections are authorised only for intravenous use and should never be administered intrathecally.

• Safety Concern: Inadvertent intrathecal administration has been associated with severe adverse reactions, including seizures, cardiac arrhythmias and fatalities.
• Labelling Update: Product information will be updated to include strengthened warnings emphasising the correct (intravenous) route of administration.
• Action Required: Healthcare professionals are advised to exercise extreme caution in the storage, handling and administration of tranexamic acid injectables.

This summary is based on a Dear Healthcare Professional Letter published on the HSA website.